Social Media Obesity Treatment for College Students



Status:Active, not recruiting
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 35
Updated:4/17/2018
Start Date:February 2015
End Date:April 2019

Use our guide to learn which trials are right for you!

Translation of Social Media Obesity Treatment Into Two College Campus Communities

This is a randomized trial designed to translate and deliver programs via social media for a
healthy body weight to university students. Specifically, in this trial, we will randomly
assign 450 overweight/obese (BMI between 25-45kg/m2) university students (ages 18-35)
enrolled at two colleges (George Washington University and University of
Massachusetts-Boston) to one of two social media weight loss treatments (personalized or
generic) or a contact control. The social media treatments consist of Facebook groups to
provide social support, connectedness and intervention content, as well as daily text
messages. Assessments will be conducted at baseline, 6, 12, and 18 months post baseline, with
the primary outcome being weight loss at 18 months. We hypothesize that: a) Tailored Social
Media will lose significantly more weight at the above time points compared with Targeted
Social Media. b) Both the Tailored Social Media and Targeted Social Media groups will have
greater weight loss at the 6, 12, 18 month follow-ups than Contact Control. The secondary aim
is to evaluate changes in metabolic risk factors among those participants who have maintained
at least 5% weight loss at 18 months. We hypothesize that participants who achieve a 5%
weight loss at 6 and 18 months will have significantly lower triglycerides, higher HDL
cholesterol, and lower blood pressure than those who do not achieve and maintain that weight
target. Finally, we will conduct additional formative work to evaluate the implementation
feasibility of this intervention on college campuses, including an assessment of costs as
well as the sustainability infrastructure using the PRISM (Practical, Robust Implementation
and Sustainability Model) model as a guide. The results of this study have the potential to
significantly impact the delivery of obesity treatment services on college campuses.


Inclusion Criteria:

1. Age 18 - 35 years old

2. BMI between 25 and 45

3. Current student at GWU, UMB, or other approved college/university in the greater
DC/Boston area available for assessments at months 6, 12 and 18

4. Fluent in English

5. Active Facebook user, as identified by current Facebook account, logged in at least
one time in the past month

6. Regular text message access

Exclusion Criteria:

1. Untreated hypertension, hyperlipidemia, or type 2 diabetes, unless permission is
provided by their health care provider. During screening visits, blood pressure will
be assessed. Individuals with blood pressure levels >140/90 mmHg, will be informed of
these levels and recommend that they contact their HCP. Study participation cannot
commence or resume without HCP consent Note: Since weight control is an appropriate
initial treatment for these medical issues, individuals can participate in the trial
if they receive permission from their HCP, and the HCP indicates that he/she will be
managing these risk factors. Participants who do not currently have a HCP will be
connected with Student Health Services on each campus.

2. Heart disease, heart problems, or participants who report being prescribed drugs for
blood pressure or a major heart condition, unless permission is received from their
HCP. [PAR-Q]

3. Health problems which may influence the ability to walk for physical activity (e.g.,
chest pain during periods of activity, loss of consciousness or losing balance due to
dizziness) or other reasons why a person should not do physical activity, unless
permission is provided by their HCP. [PAR-Q]

4. Type 1 diabetes or treatment of type 2 diabetes with insulin or oral medications that
may cause hypoglycemia (e.g. sulphonylureas). These individuals will be excluded to
mitigate concerns about hypoglycemia in a weight loss program.

5. Health problems that may be associated with unintentional weight change or affect the
safety of a weight loss program:

- Report of a heart attack or stroke

- Active tuberculosis

- HIV

- Chronic hepatitis B or C, or other chronic liver disease

- Inflammatory bowel disease requiring treatment within the 12 months

- Thyroid disease

- Renal disease

- Hospitalization for asthma or other lung disease in the past year

- Chronic use of steroid medication.

- Cancer within the past 5 years (except for non-melanoma skin cancers or early
stage cervical cancer)

6. Report of a past diagnosis of or treatment for a DSM-V eating disorder (anorexia
nervosa, bulimia nervosa, or binge eating disorder) or meet criteria as based on EDDS
screening at start of trial

7. Report of a past diagnosis of or current symptoms of alcohol or substance dependence

8. Currently pregnant, pregnant within the past 6 months, or planning to become pregnant
within the next 6 months. These individuals may later be re-screened.

9. History of schizophrenia or bipolar disorder ("manic" depression)

10. Hospitalization for depression or other psychiatric disorder within the past 12 months

11. Currently trying to gain weight, or using steroids for muscle mass or weight gain

12. Bariatric (or weight loss) Surgery

13. Participation in another weight loss or physical activity study that would interfere
with this study, or taking weight loss medication

14. A member of a participant's self-identified close social network is a participant

15. If graduate student, being in a support or evaluative role of undergraduate students
on same campus (e.g., resident advisor/director, teaching assistant, coach). If so,
this person may be excluded or asked to wait to join a cohort with students from other
universities.

16. Reason to suspect that the participant would not adhere to the study intervention or
assessment schedule

17. Medications - not stable on dosage for at least 3 months or HCP Clearance depending on
medication type.
We found this trial at
2
sites
Washington, District of Columbia 20052
Principal Investigator: Melissa Napolitao, PhD
Phone: 202-994-9099
?
mi
from
Washington,
Click here to add this to my saved trials
Boston, Massachusetts 02125
Phone: 617-287-3807
?
mi
from
Boston, MA
Click here to add this to my saved trials